[ad_1]

Novo Nordisk CEO Lars Fruegaard Jørgensen

Novo Nordisk CEO Lars Fruergaard Jørgensen.

Novo Nordisk CEO Lars Fruergaard Jørgensen stated Friday that the company’s experimental weight loss pill, Amycretin, “might develop right into a best-in-class drugs.” His comments on CNBC got here a day after the corporate’s inventory surged following the announcement of promising outcomes for the drug. That sent Novo Nordisk’s market cap past Tesla’s and made it the Twelfth-most worthwhile firm on the planet.

The drug maker advised traders on Thursday that Amycretin helped users lose an average of 13% of body weight after 12 weeks in an early-stage trial. By comparability, sufferers on the diabetes weight reduction medicine Ozempic and Wegovy, each of that are injections, lose about 6% of their weight in 12 weeks.

Jørgensen advised CNBC on Friday that the he doesn’t count on Amycretin to fully exchange Wegovy available in the market.

“We imagine sooner or later, there can be totally different segments of anti-obesity remedies, totally different sufferers having totally different preferences,” Jørgensen stated. “Some will favor an injectable. And we actually imagine {that a} once-weekly injectable is a really handy providing.”

It can take Novo Nordisk years to fulfill full demand for weight reduction medicine

Jørgensen additionally stated the hole between demand for weight reduction medicine and the availability is important and will take the trade years to shut.

He identified that there are extra 100 million folks with weight problems within the U.S. alone. Novo Nordisk at present solely serves a small inhabitants of that group, about 1 million.

“It’ll take fairly some years earlier than the trade has scaled up provides to have the ability to meet this very sturdy demand,” Jørgensen stated.

Novo Nordisk introduced in February that it has bought three facilities from the drug manufacturing company Catalent for $11 billion in an effort to handle a scarcity of Wegovy. As a part of the transaction, the corporate’s largest shareholder Novo Holdings agreed to accumulate Catalent. Novo Nordisk stated in an announcement that the acquisition will enhance the corporate’s manufacturing capability from 2026 and onwards.

Since Might 2023, Novo Nordisk has been limiting starter doses of Wegovy to make sure there may be sufficient provide for sufferers already on the drug.

[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *